Department of Medical Oncology, Bolu Abant Izzet Baysal University, 14030, Bolu, Turkey.
Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Ir J Med Sci. 2022 Aug;191(4):1561-1567. doi: 10.1007/s11845-021-02759-0. Epub 2021 Sep 1.
The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy.
A total of 86 mRCC patients were included. The expression of THSD7A in nephrectomy material of the patients was assessed by immunohistochemistry and expression patterns were categorized into two groups: negative (no staining) and positive. Univariable and multivariable Cox regression models evaluated the impact of THSD7A expression on progression free survival (PFS) and overall survival (OS) of the patients.
THSD7A expression was determined in 77.9% of the patients. Kaplan-Meier analyses showed that while the patients with THSD7A expression had significantly inferior OS times than those with negative THSD7A expression (19.9 months vs. 52.2 months, P = 0.024, respectively), there was no association between THSD7A expression and PFS. The univariate analyses demonstrated that the significant variables in predicting OS were presence of bone metastasis (P = 0.030), THSD7A expression (P = 0.028), and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (P < 0.001). However, applying multivariate analyses, the independent variables in predicting OS were THSD7A expression (HR: 2.639, P = 0.037) and IMDC scoring system (P < 0.001).
We revealed that THSD7A expression was associated with OS of mRCC patients treated with targeted therapy. There might be an important link between THSD7A expression and resistance to targeted therapy.
血小板反应蛋白 1 型结构域包含 7A（THSD7A）表达与包括肾细胞癌（RCC）在内的肿瘤的生存结局相关，但其相关性仍有待阐明。因此，我们研究了 THSD7A 对接受靶向治疗的转移性肾细胞癌（mRCC）患者结局的影响。
共纳入 86 例 mRCC 患者。通过免疫组织化学评估患者肾切除术标本中 THSD7A 的表达，将表达模式分为两组：阴性（无染色）和阳性。单变量和多变量 Cox 回归模型评估 THSD7A 表达对患者无进展生存期（PFS）和总生存期（OS）的影响。
77.9%的患者确定了 THSD7A 表达。Kaplan-Meier 分析表明，THSD7A 表达阳性的患者 OS 时间明显短于 THSD7A 表达阴性的患者（19.9 个月 vs. 52.2 个月，P=0.024），但 THSD7A 表达与 PFS 之间无关联。单变量分析表明，预测 OS 的显著变量为存在骨转移（P=0.030）、THSD7A 表达（P=0.028）和国际转移性肾细胞癌数据库联盟（IMDC）评分系统（P<0.001）。然而，多变量分析表明，预测 OS 的独立变量为 THSD7A 表达（HR：2.639，P=0.037）和 IMDC 评分系统（P<0.001）。
我们揭示了 THSD7A 表达与接受靶向治疗的 mRCC 患者的 OS 相关。THSD7A 表达与靶向治疗耐药之间可能存在重要联系。
